Study extension of Adcetris for worsening early skin sclerosis
Treatments studied
Part of Skin clinical trials.
This trial is a follow-up study that keeps studying Adcetris (brentuximab vedotin) in people with worsening diffuse cutaneous systemic sclerosis (dcSSc) who were in an earlier Adcetris study. It aims to see if the treatment continues to help your skin symptoms over time and stays safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and were enrolled in the earlier Adcetris phase II study (BV201708) at St. Joseph’s Health.
- Your mRSS score worsened by at least 4 points compared with your Week 48 score from the earlier study.
- You can sign informed consent and follow study instructions.
- Your lung tests are not too low (FVC is 40% or more, and DLCO is 30% or more).
- Your blood counts and liver enzymes are within safe ranges at screening.
- You do not have major heart, lung pressure, infection, or nerve issues that would make treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether extracorporeal photopheresis can calm disease activity in people with early diffuse skin systemic sclerosis. If you qualify, you would receive this treatment in hopes of improving active skin disease and reducing inflammation.
This trial tests a new drug called telitacicept for people with recently diagnosed, rapidly progressing systemic sclerosis (scleroderma). It aims to see if the drug can slow down skin thickening and other symptoms.
This trial tests an investigational drug called MTX-474 for people with diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The study aims to see if it can help slow or improve skin thickening and other symptoms.
This study tests whether blocking a protein called TL1A can help reduce skin thickening and improve the immune system in people with systemic sclerosis (a condition where skin becomes hard and thick). Researchers will compare skin and blood samples from people with systemic sclerosis to healthy volunteers.
This trial tests whether the drug brentuximab vedotin can help prevent lymphoma from coming back after a stem cell transplant. It is for people with a specific type of skin lymphoma called mycosis fungoides.
This Phase 2 study tests itacitinib, a targeted medicine, to see if it can safely improve diffuse systemic sclerosis (a hardening/tightening of the skin and organ involvement). You may be eligible if you have active disease or it has been present less than 3 years.
Hear when a new Diffuse Cutaneous Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.